Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2021 - 2026)

Zentalis Pharmaceuticals has reported Cash & Equivalents over the past 6 years, most recently at $31.9 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 23.85% year-over-year to $31.9 million; the TTM value through Mar 2026 reached $31.9 million, down 23.85%, while the annual FY2025 figure was $36.0 million, 6.18% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $31.9 million at Zentalis Pharmaceuticals, down from $36.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $266.6 million in Q2 2023 and troughed at $28.0 million in Q4 2023.
  • A 5-year average of $55.8 million and a median of $37.6 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 383.39% in 2023 and later plummeted 86.13% in 2024.
  • Year by year, Cash & Equivalents stood at $43.1 million in 2022, then tumbled by 34.9% to $28.0 million in 2023, then grew by 20.91% to $33.9 million in 2024, then increased by 6.18% to $36.0 million in 2025, then decreased by 11.29% to $31.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for ZNTL at $31.9 million in Q1 2026, $36.0 million in Q4 2025, and $39.1 million in Q3 2025.